Trial Profile

Phase II registration-directed trial of CH5126766 (VS-6766) in KRAS Mutant Non-Small Cell Lung Cancer.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avutometinib (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Verastem Oncology

Most Recent Events

10 Aug 2020 According to a Verastem Oncology media release, Phase 2 registration directed Trials Expected to Commence by Year End 2020 in KRAS Mutant Non-Small Cell Lung Cancer
03 Mar 2020 New trial record
28 Feb 2020 According to a Verastem Oncology media release, the company plans to initiate discussions with regulatory authorities during the first half of 2020, with the goal of commencing this registration-directed trial as soon as possible.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com